About Transcriptional adapter 3
Transcriptional adapter 3 (TADA3) is a protein
from Homo sapiens identified by UniProt accession
O75528, 432 residues long.
MolForge cross-references it against 0 known binders and
18 disease associations.
Target properties
| Protein name | Transcriptional adapter 3 |
|---|
| UniProt accession | O75528 |
|---|
| Gene | TADA3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 432 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (18)
Diseases linked to this target (Open Targets).
- breast adenocarcinoma · score 0.26
- esophageal cancer · score 0.10
- neoplasm · score 0.08
- non-small cell lung carcinoma · score 0.03
- cancer · score 0.02
- stomach neoplasm · score 0.01
- cervical carcinoma · score 0.01
- infect · score 0.01
- infection · score 0.01
- chronic gastritis · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75528-F1 | alphafold | PREDICTED | 75.45 | — |
Amino-acid sequence (432 residues)
MSELKDCPLQ FHDFKSVDHL KVCPRYTAVL ARSEDDGIGI EELDTLQLEL ETLLSSASRR LRVLEAETQI LTDWQDKKGD RRFLKLGRDH ELGAPPKHGK PKKQKLEGKA GHGPGPGPGR PKSKNLQPKI QEYEFTDDPI DVPRIPKNDA PNRFWASVEP YCADITSEEV RTLEELLKPP EDEAEHYKIP PLGKHYSQRW AQEDLLEEQK DGARAAAVAD KKKGLMGPLT ELDTKDVDAL LKKSEAQHEQ PEDGCPFGAL TQRLLQALVE ENIISPMEDS PIPDMSGKES GADGASTSPR NQNKPFSVPH TKSLESRIKE ELIAQGLLES EDRPAEDSED EVLAELRKRQ AELKALSAHN RTKKHDLLRL AKEEVSRQEL RQRVRMADNE VMDAFRKIMA ARQKKRTPTK KEKDQAWKTL KERESILKLL DG
Explore Transcriptional adapter 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets